Morphic Holding Stock Price, News & Analysis

Morphic Therapeutic has announced the commencement of the EMERALD-2 phase 2b study of MORF-057, an oral α4β7 integrin inhibitor, aimed at treating ulcerative colitis. The first patient was dosed in this global, randomized, placebo-controlled trial, which will evaluate clinical remission rates over a 12-week period. The study also includes several secondary endpoints, with top-line results expected in the first half of 2025. The company is optimistic about MORF-057's potential to offer efficacy and tolerability for patients suffering from inflammatory bowel disease.

Morphic Therapeutic (Nasdaq: MORF) announced that President Dr. Bruce Rogers will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:55 AM GMT. This event highlights Morphic's commitment to its innovative oral integrin therapies for serious chronic diseases, including autoimmune and cardiovascular conditions. Investors can access the live webcast through the Investor section of Morphic's website, with an archived replay available post-conference. For additional details about Morphic and its advancements, visit their official site.

Morphic Therapeutic reported its third quarter 2022 financial results, highlighting the completion of EMERALD-1 phase 2a trial enrollment for MORF-057, targeting ulcerative colitis. The study exceeded the initial target of 30 patients, with primary endpoint data expected in Q2 2023. The EMERALD-2 phase 2b trial is set to begin in Q4 2022. Financially, Morphic posted a net loss of $30 million ($0.78/share) and revenue of $2.1 million. R&D expenses rose to $25.2 million. The company holds $371.8 million in cash, sufficient to fund operations into H2 2025.

Morphic Therapeutic (Nasdaq: MORF) announced promising data from a phase 1 study of MORF-057, an oral α4β7 inhibitor for inflammatory bowel disease (IBD), at the ACG Annual Meeting 2022. The study highlighted the drug's effectiveness at 100 mg and 200 mg doses, showing statistically significant effects on T cell populations and receptor saturation. All doses were well tolerated, exhibiting a favorable pharmacokinetic profile. These results support ongoing phase 2 studies EMERALD-1 and EMERALD-2.

Morphic Therapeutic announced that it has completed targeted enrollment ahead of schedule for the main cohort of the EMERALD-1 Phase 2a trial involving MORF-057, an oral therapy for moderate to severe ulcerative colitis. This trial aims to assess the drug's efficacy, safety, and tolerability. A total of 30 patients are enrolled, with additional patients in screening eligible to join if criteria are met. The study investigates the impact of MORF-057 on Robarts Histopathology Index scores among other measures in a bid to validate its therapeutic potential.

Morphic Therapeutic (MORF) presented new phase 1 data for MORF-057 at UEG Week 2022, demonstrating significant receptor saturation and increases in key T lymphocyte populations. The 200 mg BID dose showed activity consistent with approved therapies for ulcerative colitis. No safety concerns were reported. This data bolsters support for the ongoing open-label phase 2a study and upcoming EMERALD-2 trial. The company’s focus on developing oral integrin therapies for serious chronic conditions, including inflammatory bowel disease, positions it favorably in the biopharmaceutical landscape.

Morphic Therapeutic (Nasdaq: MORF) celebrates Dr. Timothy A. Springer for receiving the 2022 Albert Lasker Basic Medical Research Award. This honor acknowledges his groundbreaking work on integrin receptors, crucial for treatment development in autoimmune and chronic diseases. Dr. Springer, alongside other notable scientists, contributed significantly to understanding integrin function, leading to innovative therapies. The recognition emphasizes Morphic's foundation on Dr. Springer’s research, highlighting the potential for future advancements in their oral integrin therapies, aimed at severe chronic health issues.

Morphic Therapeutic (NASDAQ: MORF) announced that its management will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 8 at 10:25 AM ET. A live webcast will be accessible on the Investor section of the company’s website, with an archived replay available post-conference. Morphic is focused on developing a new generation of oral integrin therapies aimed at treating serious chronic diseases such as autoimmune disorders, cardiovascular issues, and cancer, leveraging its proprietary MInT technology platform in collaboration with Janssen and Schrödinger.